Skip to main content
Erschienen in: International Journal of Colorectal Disease 9/2012

01.09.2012 | Review

Systematic review of medical therapy to prevent recurrent diverticulitis

verfasst von: Çagdas Ünlü, Lidewine Daniels, Bart C. Vrouenraets, Marja A. Boermeester

Erschienen in: International Journal of Colorectal Disease | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Aim and background

One of today’s controversies remains the prevention of recurrent diverticulitis. Current guidelines advise a conservative approach, based on studies showing low recurrence rates and a high operative morbidity and mortality. Conservative measures in prevention recurrence are dietary advises and medical therapies, including probiotics and 5-aminosalicylic acid.

Objectives

The aim of this systematic review is to assess whether medical or dietary therapies can prevent recurrent diverticulitis after a primary episode of acute diverticulitis.

Method and search strategy

We searched different databases for papers published between January 1966 and January 2011.

Study selection

Clinical studies were eligible for inclusion if they assessed the prevention of recurrent diverticulitis with a medical or dietary therapy. Exclusion criteria were studies without a control group.

Results

Three randomized controlled trials (RCT), all with a Jadad quality score of 2 out of 5, were included in this systematic review. Mesalazine results in significantly less disease recurrence and fewer symptoms after an acute episode. The use of probiotics decreases symptoms but does not reduce recurrence. No difference in effect is seen when Balsalazide is added to probiotics compared to probiotics only. No relevant studies on dietary therapy/advices or antibiotics for prevention of recurrent diverticulitis were found.

Conclusion

The evidence that supports medical therapy to prevent recurrent diverticulitis is of poor quality. Treatment with 5-aminosalicylic acid seems promising. Based on current data, no recommendation of any non-operative relapse prevention therapy for diverticular disease can be made.
Literatur
1.
Zurück zum Zitat Stollman NH, Raskin JB (1999) Diagnosis and management of diverticular disease of the colon in adults: ad hoc practice parameters committee of the American college of gastroenterology. Am J Gastroenterol 94:3110–3121PubMedCrossRef Stollman NH, Raskin JB (1999) Diagnosis and management of diverticular disease of the colon in adults: ad hoc practice parameters committee of the American college of gastroenterology. Am J Gastroenterol 94:3110–3121PubMedCrossRef
2.
Zurück zum Zitat Colcock BP (1958) Surgical management of complicated diverticulitis. N Engl J Med 259:570–573PubMedCrossRef Colcock BP (1958) Surgical management of complicated diverticulitis. N Engl J Med 259:570–573PubMedCrossRef
3.
Zurück zum Zitat Parks TG (1969) Natural history of diverticular disease of the colon: a review of 521 cases. Br Med J 4:639–642PubMedCrossRef Parks TG (1969) Natural history of diverticular disease of the colon: a review of 521 cases. Br Med J 4:639–642PubMedCrossRef
4.
Zurück zum Zitat Rafferty J, Shellito P, Hyman NH et al (2006) Standards Committee of the American Society of Colon and Rectal Surgeons. Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 49:939–944PubMedCrossRef Rafferty J, Shellito P, Hyman NH et al (2006) Standards Committee of the American Society of Colon and Rectal Surgeons. Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 49:939–944PubMedCrossRef
5.
Zurück zum Zitat Chautems RC, Ambrosetti P, Ludwig A et al (2002) Long term follow-up after first acute episode of sigmoid diverticulitis: is surgery mandatory? Dis Colon Rectum 45:962–966PubMedCrossRef Chautems RC, Ambrosetti P, Ludwig A et al (2002) Long term follow-up after first acute episode of sigmoid diverticulitis: is surgery mandatory? Dis Colon Rectum 45:962–966PubMedCrossRef
6.
Zurück zum Zitat Hjern F, Josephson T, Altmans D et al (2008) Outcome of younger patients with acute diverticulitis. Br J Surg 95:758–764PubMedCrossRef Hjern F, Josephson T, Altmans D et al (2008) Outcome of younger patients with acute diverticulitis. Br J Surg 95:758–764PubMedCrossRef
7.
Zurück zum Zitat Chapman J, Dozois E, Wolff B et al (2006) Diverticulitis: a progressive disease? Do multiple recurrences predict less favorable outcomes? Ann Surg 243:876–883PubMedCrossRef Chapman J, Dozois E, Wolff B et al (2006) Diverticulitis: a progressive disease? Do multiple recurrences predict less favorable outcomes? Ann Surg 243:876–883PubMedCrossRef
8.
Zurück zum Zitat Hart AR, Kennedy JH, Stebbings WS et al (2000) How frequently do large bowel diverticula perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol 12:661–666PubMedCrossRef Hart AR, Kennedy JH, Stebbings WS et al (2000) How frequently do large bowel diverticula perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol 12:661–666PubMedCrossRef
9.
Zurück zum Zitat Richards RJ, Hammitt JK (2002) Timing of prophylactic surgery in prevention of diverticulitis recurrence: a cost-effectiveness analysis. Dig Dis Sci 47:1903–1908PubMedCrossRef Richards RJ, Hammitt JK (2002) Timing of prophylactic surgery in prevention of diverticulitis recurrence: a cost-effectiveness analysis. Dig Dis Sci 47:1903–1908PubMedCrossRef
10.
Zurück zum Zitat Salem L, Veenstra DL, Sullivan SD et al (2004) The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg 199:904–912PubMedCrossRef Salem L, Veenstra DL, Sullivan SD et al (2004) The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg 199:904–912PubMedCrossRef
11.
Zurück zum Zitat Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef
12.
Zurück zum Zitat Tursi A, Brandimarte G, Daffina (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34:510–5PubMedCrossRef Tursi A, Brandimarte G, Daffina (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34:510–5PubMedCrossRef
13.
Zurück zum Zitat Dughera L, Serra AM, Battaglia E et al (2004) Acute recurrent diverticulitis is prevented by administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol 50:49–53 Dughera L, Serra AM, Battaglia E et al (2004) Acute recurrent diverticulitis is prevented by administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol 50:49–53
14.
Zurück zum Zitat Tursi A, Brandimarte G, Giorgetti GM et al (2007) Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 22:1103–1108PubMedCrossRef Tursi A, Brandimarte G, Giorgetti GM et al (2007) Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 22:1103–1108PubMedCrossRef
15.
Zurück zum Zitat Burkitt DP, Walker AR, Painter NS (1972) Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. Lancet 2:1408–1412PubMedCrossRef Burkitt DP, Walker AR, Painter NS (1972) Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. Lancet 2:1408–1412PubMedCrossRef
16.
Zurück zum Zitat Hyland JM, Taylor I (1980) Does a high fibre diet prevent the complications of diverticular disease? Br J Surg 67:77–79PubMedCrossRef Hyland JM, Taylor I (1980) Does a high fibre diet prevent the complications of diverticular disease? Br J Surg 67:77–79PubMedCrossRef
17.
Zurück zum Zitat Kohler L, Sauerland S, Neugebauer E (1999) Diagnosis and treatment of diverticular disease: results of a consensus development conference. Surg Endosc 13:430–436PubMedCrossRef Kohler L, Sauerland S, Neugebauer E (1999) Diagnosis and treatment of diverticular disease: results of a consensus development conference. Surg Endosc 13:430–436PubMedCrossRef
18.
Zurück zum Zitat Ludeman L, Warren BF, Shepherd N (2002) The pathology of diverticular disease. Best Pract Res Clin Gastroenterol 16:543–562PubMedCrossRef Ludeman L, Warren BF, Shepherd N (2002) The pathology of diverticular disease. Best Pract Res Clin Gastroenterol 16:543–562PubMedCrossRef
19.
Zurück zum Zitat Sheperd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802CrossRef Sheperd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802CrossRef
20.
21.
Zurück zum Zitat Tursi A, Brandimarte G, Giorgetti GM et al (2006) Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 52:671–674CrossRef Tursi A, Brandimarte G, Giorgetti GM et al (2006) Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 52:671–674CrossRef
22.
Zurück zum Zitat Di Mario F, Aragona G, Leandro G et al (2005) Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 50:581–586PubMedCrossRef Di Mario F, Aragona G, Leandro G et al (2005) Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 50:581–586PubMedCrossRef
23.
Zurück zum Zitat Tursi A, Brandimarte G, Giorgetti GM et al (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 40:312–316PubMedCrossRef Tursi A, Brandimarte G, Giorgetti GM et al (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 40:312–316PubMedCrossRef
24.
Zurück zum Zitat Comparato G, Fanigliulo L, Cavallaro LG et al (2007) Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 52:2934–2941PubMedCrossRef Comparato G, Fanigliulo L, Cavallaro LG et al (2007) Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 52:2934–2941PubMedCrossRef
26.
Zurück zum Zitat Floch MH, Bina I (2004) The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 38:S2–S7PubMedCrossRef Floch MH, Bina I (2004) The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 38:S2–S7PubMedCrossRef
27.
Zurück zum Zitat Frič P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313–315PubMedCrossRef Frič P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313–315PubMedCrossRef
28.
Zurück zum Zitat Lamiki P, Tsuchiya J, Pathak S et al (2010) Probiotics in Diverticular Disease of the Colon: an Open Label Study. J Gastrointest Liver Dis 19(1):31–6 Lamiki P, Tsuchiya J, Pathak S et al (2010) Probiotics in Diverticular Disease of the Colon: an Open Label Study. J Gastrointest Liver Dis 19(1):31–6
29.
Zurück zum Zitat Papi C, Ciaco A, Koch M et al (1992) Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Ital J Gastroenterol 24:452–456PubMed Papi C, Ciaco A, Koch M et al (1992) Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Ital J Gastroenterol 24:452–456PubMed
30.
Zurück zum Zitat Latella G, Pimpo MT, Sottili S et al (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55–62PubMedCrossRef Latella G, Pimpo MT, Sottili S et al (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55–62PubMedCrossRef
31.
Zurück zum Zitat Papi C, Ciaco A, Koch M et al (1995) Diverticular Disease Study Group: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre doubleblind placebo-controlled trial. Aliment Pharmacol Ther 9:33PubMedCrossRef Papi C, Ciaco A, Koch M et al (1995) Diverticular Disease Study Group: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre doubleblind placebo-controlled trial. Aliment Pharmacol Ther 9:33PubMedCrossRef
32.
Zurück zum Zitat Porta E, Germano A, Ferrieri A et al (1994) The natural history of diverticular disease of the colon: a rol for antibiotics in preventinbg complications? Eur Rev Med Pharmacol Sci 16:33–39 Porta E, Germano A, Ferrieri A et al (1994) The natural history of diverticular disease of the colon: a rol for antibiotics in preventinbg complications? Eur Rev Med Pharmacol Sci 16:33–39
33.
Zurück zum Zitat Andeweg CS, Knobben L, Hendriks JC, Bleichrodt RP, van Goor H (2011) How to diagnose acute left-sided colonic diverticulitis: proposal for a clinical scoring system. Ann Surg 253(5):940–6PubMedCrossRef Andeweg CS, Knobben L, Hendriks JC, Bleichrodt RP, van Goor H (2011) How to diagnose acute left-sided colonic diverticulitis: proposal for a clinical scoring system. Ann Surg 253(5):940–6PubMedCrossRef
34.
Zurück zum Zitat Lameris W, van Randen A, van Gulik TM, Busch OR, Winkelhagen J, Bossuyt PM et al (2010) A clinical decision rule to establish the diagnosis of acute diverticulitis at the emergency department. Dis Colon Rectum 53:896–904PubMedCrossRef Lameris W, van Randen A, van Gulik TM, Busch OR, Winkelhagen J, Bossuyt PM et al (2010) A clinical decision rule to establish the diagnosis of acute diverticulitis at the emergency department. Dis Colon Rectum 53:896–904PubMedCrossRef
35.
Zurück zum Zitat Phase III, randomised double blind dose–response stratified placebo controlled study of evaluating the safety and efficacy of SPD476 versus placebo over 104 weeks in the prevention of recurrence of diverticulitis (PREVENT 2). Clinical.Trials. gov.Identifier (http://www.clinicaltrials.gov): NCT00545103. Principal Investigator: Raskin JB, University of Miami Miller School of Medicine, USA Phase III, randomised double blind dose–response stratified placebo controlled study of evaluating the safety and efficacy of SPD476 versus placebo over 104 weeks in the prevention of recurrence of diverticulitis (PREVENT 2). Clinical.Trials. gov.Identifier (http://​www.​clinicaltrials.​gov): NCT00545103. Principal Investigator: Raskin JB, University of Miami Miller School of Medicine, USA
Metadaten
Titel
Systematic review of medical therapy to prevent recurrent diverticulitis
verfasst von
Çagdas Ünlü
Lidewine Daniels
Bart C. Vrouenraets
Marja A. Boermeester
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 9/2012
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-012-1486-7

Weitere Artikel der Ausgabe 9/2012

International Journal of Colorectal Disease 9/2012 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.